These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27003179)

  • 1. Multimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's Disease.
    Cong L; Muir ER; Chen C; Qian Y; Liu J; Biju KC; Clark RA; Li S; Duong TQ
    PLoS One; 2016; 11(3):e0151884. PubMed ID: 27003179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
    Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.
    Branch SY; Chen C; Sharma R; Lechleiter JD; Li S; Beckstead MJ
    J Neurosci; 2016 Apr; 36(14):4026-37. PubMed ID: 27053209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease.
    Galter D; Pernold K; Yoshitake T; Lindqvist E; Hoffer B; Kehr J; Larsson NG; Olson L
    Genes Brain Behav; 2010 Mar; 9(2):173-81. PubMed ID: 20002202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
    Langley MR; Ghaisas S; Palanisamy BN; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Exp Neurol; 2021 Jul; 341():113716. PubMed ID: 33839143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease.
    Good CH; Hoffman AF; Hoffer BJ; Chefer VI; Shippenberg TS; Bäckman CM; Larsson NG; Olson L; Gellhaar S; Galter D; Lupica CR
    FASEB J; 2011 Apr; 25(4):1333-44. PubMed ID: 21233488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.
    Langley M; Ghosh A; Charli A; Sarkar S; Ay M; Luo J; Zielonka J; Brenza T; Bennett B; Jin H; Ghaisas S; Schlichtmann B; Kim D; Anantharam V; Kanthasamy A; Narasimhan B; Kalyanaraman B; Kanthasamy AG
    Antioxid Redox Signal; 2017 Nov; 27(14):1048-1066. PubMed ID: 28375739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model.
    Lynch WB; Tschumi CW; Sharpe AL; Branch SY; Chen C; Ge G; Li S; Beckstead MJ
    Mov Disord; 2018 Dec; 33(12):1928-1937. PubMed ID: 30440089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.
    Beckstead MJ; Howell RD
    Exp Neurol; 2021 Jul; 341():113707. PubMed ID: 33753138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease.
    Du G; Lewis MM; Styner M; Shaffer ML; Sen S; Yang QX; Huang X
    Mov Disord; 2011 Aug; 26(9):1627-32. PubMed ID: 21618607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease.
    Li X; Redus L; Chen C; Martinez PA; Strong R; Li S; O'Connor JC
    PLoS One; 2013; 8(8):e71341. PubMed ID: 23977020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinson's disease.
    Lai JH; Chen KY; Wu JC; Olson L; Brené S; Huang CZ; Chen YH; Kang SJ; Ma KH; Hoffer BJ; Hsieh TH; Chiang YH
    Brain Res; 2019 Oct; 1720():146301. PubMed ID: 31226324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In search of early neuroradiological biomarkers for Parkinson's Disease: Alterations in resting state functional connectivity and gray matter microarchitecture in PINK1 -/- rats.
    Cai X; Qiao J; Knox T; Iriah S; Kulkarni P; Madularu D; Morrison T; Waszczak B; Hartner JC; Ferris CF
    Brain Res; 2019 Mar; 1706():58-67. PubMed ID: 30389398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.